Zhejiang Hisun Pharmaceutical (600267.SH) releases a forecasted profit, estimating a net profit of 570-630 million yuan in 2024, turning losses into profits.
Guangzhou Pharmaceuticals Corporation (stock code: 600267.SH) announced that the company is expected to achieve attributable net profit to shareholders of the listed company for the year 2024...
Zhejiang Hisun Pharmaceutical (600267.SH) announced that the company expects to achieve a net profit attributable to shareholders of the listed company of 570 million to 630 million yuan in 2024, compared to a loss in the same period last year.
Related Articles
Shenzhen New Industries Biomedical Engineering (300832.SZ) has obtained a medical device registration certificate.
RSUN PPT(01996): The requested hearing has been postponed to March 23, 2026.
EDIANYUN (02416) spent 729,800 Hong Kong dollars on September 16 to repurchase 327,000 shares.
Shenzhen New Industries Biomedical Engineering (300832.SZ) has obtained a medical device registration certificate.
RSUN PPT(01996): The requested hearing has been postponed to March 23, 2026.
EDIANYUN (02416) spent 729,800 Hong Kong dollars on September 16 to repurchase 327,000 shares.
